First Horizon Corp Biomarin Pharmaceutical Inc Transaction History

First Horizon Corp

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Oct 24, 2025	SELL	$52.62 - $61.93 $16,733 - $19,693	-318 Closed	0 $0
Q1 2021 May 11, 2021	SELL	$74.73 - $90.69 $16,963 - $20,586	-227 Reduced 41.65%	318 $24,000
Q4 2020 Feb 11, 2021	BUY	$72.61 - $90.2 $3,557 - $4,419	49 Added 9.88%	545 $47,000
Q3 2020 Nov 12, 2020	BUY	$71.87 - $131.03 $35,647 - $64,990	496 New	496 $37,000

689

187M

1.31M

1.1M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $9.79B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of First Horizon Corp, based on Form 13F filings with the SEC.

Stay updated on First Horizon Corp with notifications on news.